Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to 7-deazapurine derivatives which are useful as an antitumor agent.
• Natural modified bases are widely distributed in the animal, vegetable and microbial kingdoms as the constituent base for the first letter of the anticodons for specific tRNA (tRNA Tyr , tRNA His , tRNA Asp and tRNA Asn ). These Q bases are thought to exert directly important biological effects over the functions of tRNA converting the recognition of the genetic information from mRNA and protein synthesis.
• the present inventors after synthesis of various derivatives of Q basesand intensive research into effects of these on cancer cells, found compounds which exhibit improved antitumor activities based on the novel mechanism of action. The finding was followed by further research, which led to completion ofthis invention.
• the present invention is concerned with 7-deazapurine derivatives of the formula: ##STR3## wherein R 1 is phenyl which has, at the ortho position and/or para position as substituent(s), at least one group represented by the formula --O--R 3 , --S--R 4 or ##STR4## (wherein R 3 , R 4 , R 5 and R 6 are the same or different and each is hydrogen or an alkyl or phenyl group which may be substituted, wherein R 5 and R 6 , together with the adjacent nitrogen atom, may form a cyclic amino group, and R 3 , R 4 , R 5 and R 6 each may represent a protective group) and may have one, two or three groups with a molecular weight of up to about 200 as a substituent at any position other than those having the said substituents; R 2 is an amino group which may be protected or its salt.
• the alkyl or phenyl group which may be substituted as represented by R 3 , R 4 , R 5 and R 6 includes preferably one of those having a molecular weight of not more than about 400.
• the said alkyl group is preferably one of those having 1 to 24 carbon atoms, and their examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octadecyl, nonadecyl, eicosanyl, heneicosanyl, decosanyl, tricosanyl, tetracosanyl, 1,2-dimethylpropyl, 1-ethylpropyl, 1,2,2-trimethylpropyl, 1-propylbutyl, 2-ethylhexyl, etc.
• R 5 and R 6 together with the adjacent nitrogen atom, may form a ring.
• a ring includes for example about 5-or 6-membered cyclic amino groups, which may have a second cyclic hetero atom (e.g., N, O) in addition to the above nitrogen atom.
• Their examples include, for example, pyrrolidinyl, pyrrolinyl, pyrrolyl, imidazolidinyl, imidazolyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, morpholino, dihydropyridyl, piperidino, N-methylpiperazinyl, N-ethylpiperazinyl, etc.
• the group which may be substituted on the said alkyl or phenyl group or the cyclic amino group to be formed by R 5 and R 6 together with the adjacent nitrogen atom includes, for example, alkyl group of 1 to 4 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, sec-butyl, tert-butyl), alkenyl group of 2 to 4 carbon atoms (e.g., vinyl, allyl, 1-methylvinyl, 2-methylvinyl), cycloalkyl groups of 3 to 6 carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), cycloalkenyl groups of 5 to 6 carbon atoms (e.g., cyclopentenyl, cyclohexenyl), aralkyl-groups of 7 to 8 carbon atoms (e.g., benzyl, ⁇ -methyl
• substituents those susceptible of further substitution may be substituted by one or two alkyl groups of about 1 to 4 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl), methoxy group, ethoxy group, halogen atoms (e.g., fluorine, chlorine, bromine, iodine) and/or water-soluble groups (e.g., hydroxyl, carboxyl, sulfo, phosphono, amidino, amino, methylamino, ethylamino, dimethylamino, diethylamino, morpholino, piperidyl, N-methylpiperazin
• R 3 , R 4 , R 5 and R 6 each represents a protective group
• acyl groups e.g., formyl, acetyl, monochloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, benzoyl, o-nitrophenoxyacetyl, p-anisoyl
• diacyl groups e.g., succinoyl, phthaloyl
• alkoxycarbonyl groups e.g., methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, ⁇ -methylsulfonylethoxycarbonyl, t-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, ⁇ -(p-toluenesulfonyl)ethoxycarbonyl
• acyl groups e.g., formyl
• protective groups include, for example, formyl, acetyl, monochloroacetyl, trifluoroacetyl, benzoyl, p-anisoyl, phthaloyl, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, t-butoxycarbonyl, benzyloxycarbonyl, phenoxycarbonyl, benzyl, p-methoxybenzyl, p-chlorobenzyl, p-nitrobenzyl, t-butyldimethylsilyl, trityl, methoxymethyl, isopropyloxymethyl, tetrahydropyranyl, methyl, t-butyl, carbamoyl, N,N-dimethylcarbamoyl and sulfo.
• R 1 is phenyl which has, at the ortho position and/or para position as a substituent, at least one group by the formula --O--R 3 , --S--R 4 , ##STR5## wherein R 3' is alkyl of 5 to 24 carbon atoms, alkyl of 1 to 24 carbon atoms which is substituted or phenyl which may be substituted,
• R 4 is hydrogen or an alkyl or phenyl group which may be substituted
• R 5' and R 6' are the same or different and each is alkyl of 5 to 24 carbon atoms, alkyl of 1 to 24 carbon atoms which is substituted or phenyl which may be substituted, whereby R 5 and R 6 , together with the adjacent nitrogen atom, may form a cyclic amino group which may be substituted, and R 3' , R 4 , R 5 ' and R 6 ' each may represent a protective group.
• R 1 has, at the ortho position and/or para position as a substituent, at least one group represented by --O--R 3 , --S--R 4 or ##STR6## (wherein R 3 , R 4 , R 5 and R 6 are as defined hereinbefore), preferred examples of such a substituent include, for example, hydroxy, methoxy, ethoxy, propyloxy, butyloxy, octyloxy, phenoxy, benzyloxy, mercapto, methylthio, ethylthio, propylthio, butylthio, decylthio, phenylthio, amino, methylamino, ethylamino, propylamino, butylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino, phenylamino, formyloxy, acetyloxy, propiony
• Preferable examples of the 5- or 6-membered ring which R 5 and R 6 together with the adjacent nitrogen atom form include, for example, pyrrolidinyl, pyrrolyl, imidazolyl, morpholino, piperidino, N-methylpiperazinyl and N-ethylpiperazinyl.
• substituents include octyloxy, phenoxy, benzyloxy, mercapto, methylthio, ethylthio, propylthio, butylthio, decylthio, phenylthio, phenylamino, formyloxy, acetyloxy, propionyloxy, butyryloxy, benzoyloxy, formamido, acetamido, trifluoroacetamido, benzamido, pyrrolidinyl, pyrrolyl, imidazolyl, morpholino, piperidino, N-methylpiperazinyl and N-ethylpiperazinyl.
• the further preferable examples of such a substituent include mercapto, methylthio, acetylthio, propionyloxy, butyryloxy, acetamido, trifluoroacetamido, pyrrolyl, morpholino and N-methylpiperazinyl.
• the phenyl represented by R 1 which, as described hereinbefore, has at least one group represented by the formula --O--R 3 , --S--R 4 or ##STR7## (wherein R 3 , R 4 , R 5 and R 6 are as defined hereinbfore) at the ortho position and/or para position, has two or three of the above groups at the ortho position and/or para position, the said groups may be the same or different.
• the group with a molecular weight of up to about 200 which the phenyl represented by R 1 may have as a substituent at a position other than the ortho position and/or para position having at least one substituent of the formula --O--R 3 , --S--R 4 or ##STR8## includes, for example, alkyl groups of 1 to 12 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl), alkenyl groups of 2 to 12 carbon atoms (e.g., vinyl, allyl, 1-methylvinyl, 2-methylvinyl, 1-octenyl, 1-decenyl), cycl
• phenyl, naphthyl, alkoxy groups of 1 to 4 carbon atoms e.g., methoxy, ethoxy, propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy
• phenoxy group alkanoyl groups of 1 to 4 carbon atoms (e.g., formyl, acetyl, propionyl, n-butyryl, iso-butyryl), benzoyl group, alkanoyloxy groups of 1 to 4 carbon atoms (e.g., formyloxy, acetyloxy, propionyloxy, n-butyryloxy, iso-butyryloxy), benzoyloxy group, carboxy group, alkoxycarbonyl groups of 2 to 4 carbon atoms (e.g., methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, iso-propoxycarbonyl, n-
• those capable of undergoing further substitution may be substituted by one or two of alkyl groups of 1 to 4 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl), methoxy group, ethoxy group, halogen atoms (e.g., fluorine, chlorine, bromine, iodine) and/or water-soluble groups (e.g., hydroxy, carboxyl, sulfo, phosphono, amidino, amino, methylamino, ethylamino, dimethylamino, diethylamino, morpholino, piperidyl, N-methylpiperazinyl, pyridyl, trimethylammonium, triethylammonium, pyridinium groups).
• alkyl groups of 1 to 4 carbon atoms e.g., methyl, ethy
• Preferable examples of the group with a molecular weight of up to about 200 which may be carried by the phenyl represented by R 1 as mentioned above include, for example, methyl, ethyl, propyl, butyl, vinyl, allyl, cyclopentyl, cyclohexyl, benzyl, phenyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, phenoxy, formyl, acetyl, benzoyl, acetyloxy, carboxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, carbamoyl, halogens, nitro, cyano, trifloromethyl, amino, methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino,
• the phenyl represented by R 1 has at least one group --O--R 3 , --S--R 4 or ##STR9## (wherein R 3 , R 4 , R 5 and R 6 are as defined hereinbefore) at the ortho position and/or para position, but may also have at least one group --O--R 3 , --S--R 4 or ##STR10## being substituted at the ortho position and/or para position and the above-described group or groups with a molecular weight of up to about 200 being substituted at the remaining ortho position and/or para position.
• the protective group in the amino group which may be protected as represented by R 2 includes, for example, acyl group, alkoxycarbonyl groups, aryloxycarbonyl groups, N-substituted carbamoyl groups, thioalkoxycarbonyl groups, thioaryloxycarbonyl groups, arylmethyl groups, N,N-dialkylaminomethylene groups, diphenylaminomethylene, phosphoryl group which may have one or two benzyl, sulfo, alkylsulfonyl, arylsulfonyl group, and tri(C 1-4 alkyl)silyl group.
• the acyl groups as the said protective group are preferably those with a molecular weight of not more than about 400, and their specific examples include, for example, alkanoyl groups and aroyl groups.
• the above-described alkanoyl groups are preferably those of 1 to 18 carbon atoms, and their examples include, for example, formyl, acetyl, monochloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, propionyl, butyryl, isobutyryl, succinyl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, 2-ethylhexanoyl, nonanoyl, decanoyl, undecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl
• aroyl groups are preferably those of 7 to 12 carbon atoms, and their examples include, for example, benzoyl, o-anisoyl, o-cyanobenzoyl, o-nitrobenzoyl, toluoyl, phthaloyl and naphthoyl, with benzoyl group being among others conveniently employed.
• the alkoxycarbonyl groups are preferably those of 1 to 15 carbon atoms, and their examples include, for example, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, ⁇ -methylsulfonylethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, 2-(p-xenyl)isopropoxycarbonyl and ⁇ -(p-toluenesulfonyl)ethoxycarbonyl, with tert-butoxycarbonyl benzyloxycarbonyl, etc.
• the aryloxycarbonyl groups are preferably those of 6 to 12 carbon atoms, and their examples include, for example, phenoxycarbonyl, p-methoxyphenoxycarbonyl, ⁇ -naphthoxycarbonyl and ⁇ -naphthoxycarbonyl.
• N,N-substituted carbamoyl groups there are used, for example, piperidinocarbonyl and N,N-diphenylcarbamoyl.
• the thioalkoxycarbonyl groups are preferably those of 1 to 7 carbon atoms, and their examples include, for example, thiomethoxycarbonyl, thioethoxycarbonyl, thiopropoxycarbonyl, thiobutoxycarbonyl and thiobenzyloxycarbonyl, with thiobenzyloxycarbon, etc. being among others conveniently employed.
• thioaryloxycarbonyl groups there are used, for example, thiophenoxycarbonyl, thio- ⁇ -naphthoxycarbonyl and thio- ⁇ -naphthoxycarbonyl.
• arylmethyl groups there are used, for example, benzyl, p-methoxybenzyl, 3,4,5-trimethyoxybenzyl, di(p-methoxybenzyl)methyl, trityl and monomethoxytrityl.
• N,N-dialkylaminomethylene groups there are used, for example, dimethylaminomethylene, diethylaminomethylene, dipropylaminomethylene and diphenylaminomethylene.
• phosphoryl groups there are used, for example, p-nitrobenzylphosphoryl, p-bromobenzylphosphoryl, dibenzylphosphoryl, di(p-nitrobenzyl)phosphoryl, di(o-bromobenzyl)phosphoryl and di(p-iodobenzyl)phosphoryl.
• the sulfonyl groups include, for example, sulfo, benzylsulfonyl, phenacylsulfonyl groups suflonyl and toluenesulfonyl.
• the trialkylsilyl groups include, for example, trimethylsilyl and tert-butyldimethylsilyl.
• the protective groups at the amino group which may be protected as represented by R 2 include formyl, acetyl, monochloroacetyl, trifluoroacetyl, octanoyl, 2-ethylhexanoyl, benzoyl, p-anisoyl, phthaloyl, methoxycarbonyl, ethoxycarbonyl, 2,2,2trichloroethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, ⁇ -methylsulfonylethoxycarbonyl, phenoxycarbonyl, dimethylaminomethylene, etc.
• the more preferable examples of the protective groups include acetyl, monochloroacetyl, octanoyl, benzoyl and dimethylaminomethylene.
• the compound (I) of the present invention can be readily produced, for example, by the following method of synthesis.
• 7-deazapurine derivatives of the formula (I) can be obtained by subjecting a compound of the formula: ##STR11## [wherein R 2 is as defined hereinbefore; R 7 and R 8 each is an alkyl, alkenyl or aralkyl group having a methylene group in the ⁇ position, or both of R 7 and R 8 , together with the adjacent nitrogen atom, may form a cyclic amino group] or its salt to a substitution reaction with an amine of the formula:
• R 1 is as defined hereinbefore or its salt, and subsequehtly subjecting the reaction product to a deprotection reaction, if desired, in cases R 2 is a protected amino group.
• the individual groups represented by R 7 and R 8 may be the same or different, and the alkyl group having a methylene group in the ⁇ position includes those of 1 to 10 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, octyl, nonyl and decyl, with alkyl groups of 1 to 6 carbon atoms being among others conveniently used.
• the alkenyl groups having a methylene group in the ⁇ position include, for example, those of 3 to 13 carbon atoms, such as allyl(2-propenyl), 2-butenyl, 2-pentenyl, 2-hexenyl, 4-propyl-2-pentenyl, cinnamyl and 2-nonyl-2-butenyl, and among others, alkenyl groups of 3 to 9 carbon atoms are conveniently employed.
• alkyl and alkenyl groups may have a substituent or substituents in any position other than the ⁇ position, and such a substituent or substituents include alkyl groups of 1 to 4 carbon atoms (e.g., methyl, ethyl, propyl, isoproyl, butyl, isobutyl, sec-butyl, tert-butyl), alkoxy groups of 1 to 4 carbon atoms (e.g., methoxy, ethoxy, propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy), alkanoyl groups of 1 to 4 carbon atoms (e.g., formyl, acetyl, propionyl, n-butyryl, iso-butyryl), hydroxy group, nitro group, halogens (e.g., fluorine, chlorine, bromine, iodine), cyano group, trifluoromethyl group
• the aralkyl groups having a methylene groupin the ⁇ position as represented by R 7 and R 8 include those of about 7 to 12 carbon atoms, such as benzyl, phenethyl, 3-phenylpropyl, naphthylmethyl and naphthylethyl, and among others, benzyl group is conveniently used.
• These aralkyl groups may also have a substituent or substituents in the alkylene chain and/or aryl (phenyl) ring moiety other than the ⁇ position, and these substituents include the groups as exemplified in the above for the alkyl and alkenyl groups.
• the cyclic amino group which R 7 and R 8 together with the adjacent nitrogen atom form includes, for example, 5- or 6-membered cyclic amino groups, and they may carry a second cyclic hetero atom (e.g., N, O) in addition to the above nitrogen atom.
• a second cyclic hetero atom e.g., N, O
• Such cyclic amino groups include, for example, 1-pyrrolidinyl, 1-pyrrolinyl, 1-imidazolidinyl, 1-imidazolinyl, 1-pyrazolidinyl, 1-pyrazolinyl, morpholino, piperidino and 1-piperazinyl, and these cyclio amino groups may have a substituent or substituents at any position other than the position ( ⁇ position) adjacent to the nitrogen atom; such substituents include the groups as exemplified in the above for the alkyl and alkenyl groups.
• substitution reaction between the compound (II) or a salt thereof and the compound (III) or a salt thereof as mentioned above can be effected, for example, by allowing both of the compounds to react at a ratio of the compound (III)/the compound (II) in the range of about 1 to 20 (molar ratio) in the absence or presence of a suitable reaction solvent employed at a reaction temperature within the range of about 0° C. to the boiling point of such a reaction solvent, preferably about 20° to 100° C., for about 1 hour to 5 days.
• the reaction can be allowed to proceed under milder reaction conditions.
• the resultant quaternary salt of the compound (II) may be isolated or subjected, directly without elimination, to the substitution reaction with the compound (III).
• reaction solvent to be used in the substitution reaction between the compound (II) and the compound (III) there are used, for example, water, methanol, ethanol, propanol, butanol, pentanol, tetrahydrofurane, dioxane, acetonitrile, pyridine, dimethylformamide, dimethylsulfoxide, sulfolane or suitable solvent mixtures thereof.
• the objective compound (I) or its salt can be advantageously produced by adjusting to the optimal pH (normally, to a pH of about 5 to 13) with a base (e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, triethylamine, N-methylmorpholine) or a salt (e.g., sodium chloride, potassium chloride, calcium chloride, sodium carbonate, potassium carbonate, sodium hydrogencarbonate).
• a base e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, triethylamine, N-methylmorpholine
• a salt e.g., sodium chloride, potassium chloride, calcium chloride, sodium carbonate, potassium carbonate, sodium hydrogencarbonate.
• the group which is carried on the phenyl represented by R 1 is a hydroxy, amino, mono-substituted amino, mercapto, carboxy, sulfo, phosphono or formyl group or R 3 , R 4 , R 5 or R 6 each is a group containing as a substituent a hydroxy, amino, monosubstituted amino, mercapto, carboxy, sulfo, phosphono or formyl group, the group R 1 in the compound (III) may be one of those having these substituents protected with protective groups.
• the above described protective groups include the protective groups as exemplified in the above when R 3 , R 4 , R 5 or R 6 each represents a protective group.
• the above protective group is a carboxy, sulfo or phosphono group
• these groups can be converted to ester groups (e.g., methyl ester, ethyl ester, t-butyl ester, phenyl, benzyl ester), and in the case of it being a formyl group, the said formyl group can be converted to an acetal group (e.g., methyl acetal, ethyl acetal), to provide protection.
• ester groups e.g., methyl ester, ethyl ester, t-butyl ester, phenyl, benzyl ester
• an acetal group e.g., methyl acetal, ethyl acetal
• substituent conversion include, for example, conversions from nitro group into amino group, from alkanoylamido group into amino group, from amino group into mono-substituted amino group, di-substituted amino group, alkanoylamido group, halogen atom, hydroxyl group or cyano group, from cyano group into carbamoyl group, alkoxycarbonyl group or carboxy group, from hydroxy group into alkoxy group or alkanoyloxy group and from alkoxy group into hydroxy group [refer to S. H. Pyne, J. B. Hendrickson, D. J. Cram and G. S. Hammond, "Organic Chemistry” (4th edition) [I] and [II], Hirokawa Shoten Co. (1982)].
• the starting compounds (II) to be used in the above described methods can be readily produced by the methods known in the literature [refer to the Japanese Unexamined Patent Publication No. 157790/1983 which corresponds to U.S. Pat. No. 4,571,423].
• the 7-deazapurine derivatives (I) as produced in accordance with the method of the present invention can be isolated from the reaction mixture by usual separation and purification means, such as concentration, solvent extraction, chromatography and recrystallization.
• separation and purification means such as concentration, solvent extraction, chromatography and recrystallization.
• Pharmaceutically acceptable salts of the compounds (I) include, for example, salts with such mineral acids as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and boric acid, salts with such organic acids as oxalic acid, tartaric acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and camphorsulfonic acid, and quaternary salts with methyl bromide, methyl iodide, methyl methanesulfonate, methyl benzenesulfonate, p-sulfonates, etc.
• mineral acids as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and boric acid
• salts with such organic acids as oxalic acid, tartaric acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, benzenes
• the thus-obtained compounds (I) or salts thereof inhibit markedly a growth of cultured L5178Y cells in vitro as well as a growth of Meth A, Sarcoma, etc. in vivo.
• the compounds (I) or salts thereof when intraperitoneally administered to mice in a dose of 200 mg/kg, do not cause any death.
• the compounds (I) or salts thereof can be used as an antitumor agent for the purpose of treatment of tumors in warm-blooded animals, especially mammals (e.g., mice, rats, cats, dogs, rabbits, etc.)
• mammals e.g., mice, rats, cats, dogs, rabbits, etc.
• an antitumor agent In using as an antitumor agent, they can be administered orally or parenterally, either as such or in the dosage forms, such as powders, granules, tablets, capsules, suppositories and injections, which are prepared in the conventional manner with use of pharmacologically acceptable carriers, excipients, diluents, etc.
• Their dose varies with the animal to be treated, the conditions and severity of the disease, the kind of the compounds, the route of administration and other factors, and generally comprises about 10 to 200 mg/kg of body weight per day as the compound (I) in the case of oral administration and about 10 to 100 mg/kg of body weight per day as the compound (I) in the case of parenteral administration.
• the compounds (I) or salts thereof possess antiviral and antimicrobial activities against various viruses and microbes, such as Xanthomonas oryzae, Pyricularia oryzae, Escherichia coli or Serratia marcescens. Since the compounds (I) are low in toxicity as described above, the compound (I) can be employed as an antiviral agent, antimicrobial agent or disinfectant intended for the prevention and treatment of viral and bacterial infectious diseases in warm-blooded animals, particularly in mammals (e.g., mice, rats, cats, dogs, rabbits, human).
• mammals e.g., mice, rats, cats, dogs, rabbits, human.
• the compounds (I) or salts thereof, in using them as an antimicrobial agent or disinfectant are formulated e.g. into liquid preparations containing the compound (I) or a salt thereof in the concentration of about 0.5 to 500 mg/ml in water, an aqueous solution such as isotonic glucose solution and Ringer solution, or a nonaqueous solution such as a vegetable (e.g., cotton seed, peanut, corn, sesame) fatty oil, and such preparations can be applied to the hand, foot, ear and other parts of mammals for sterilization and disinfection of such applied parts.
• aqueous solution such as isotonic glucose solution and Ringer solution
• a nonaqueous solution such as a vegetable (e.g., cotton seed, peanut, corn, sesame) fatty oil
• the compounds (I) or salts thereof after being formulated into tablets containing about 0.5 to 500 mg of the compound (I) or a salt thereof in an excipient such as lactose, starch and talc, can be used orally in the prevention and treatment of viral and bacterial infectious diseases in mammals.
• the dose is about 10 to 200 mg/kg of body weight per day as the compound (I).
• the compounds (I), particularly the compounds (I) wherein R 2 is a protected amino group can be used as an intermediate for the synthesis of useful drugs.
• [ 3 H] guanine labeled tRNA*) (8000 cpm), 70 mM of hydrochloride, 60 mM of magnesium chloride, 0.5 unit of rat liver tRNA-guanine transglycosylase and 0.02 OD 260 of the compound obtained in Example 1 to be described hereinafter were prepared to the total volume of 100 ⁇ l, and the reaction was allowed to proceed at 37° C. for 17 hours.
• the reaction solution was applied to a Whatman 3 MM filter paper (produced by Whatman Co., U.S.A.), which was washed three times with a 5% aqueous solution of trichloroacetic acid and once successively with ethanol/ether (1:1) and ether alone. After drying, the uptake of the test compound was determined in a toluenic scintillation fluid, and it was found that the compound of Example 1 had been taken up in 120% of tRNA.
• the dilutions were further incubated for 72 hours, at the end of which time the cells were counted with use of a counter and the IC 50 (50% growth inhibitory concentration) was calculated with the count for the non-treated control group being taken as 100%.
• the IC 50 value was 2.0 ⁇ g/ml.
• the compound (1.06 g) is suspended in a mixed solution (1:1, 800 ml) of methanol/tetrahydrofuran, and aqueous concentrated ammonia (100 ml) is added to the suspension, followed by stirring at room temperature for 6 days.
• the reaction solution is concentrated to dryness under reduced pressure, and after methanol, tetrahydrofuran and ethyl ether are added to the residue, the resulting precipitate is collected by filtration to give the objective compound (0.623 g).
• IR ⁇ 1665, 1600, 1510, 1220 cm -1 .
• IR ⁇ 1653, 1615, 1500, 1210 cm -1 .
• the compound (1.09 g) is dissolved in a mixed solution (1:1, 100 ml) of methanol/tetrahydrofuran, and after the inside of the reaction system is replaced with nitrogen, concentrated aqueous ammonia (20 ml) is added, followed by stirring at room temperature for 48 hours.
• the reaction solution is concentrated to dryness under reduced pressure, and the precipitate, which separates out upon addition to the residue of methanol, tetrahydrofuran and ethyl ether, is collected by filtration to give the objective compound (0.536 g).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=13960021

Family Applications (1)

Country Status (4)

Cited By (1)

Families Citing this family (3)

Citations (5)

Family Cites Families (2)

• 1984
  • 1984-05-02 JP JP59089049A patent/JPS60233080A/ja active Granted
• 1985
  • 1985-04-27 EP EP85105173A patent/EP0160910A3/en not_active Withdrawn
  • 1985-05-01 US US06/729,202 patent/US4650868A/en not_active Expired - Fee Related
  • 1985-05-01 CA CA000480507A patent/CA1247094A/en not_active Expired

Patent Citations (8)

Also Published As

Similar Documents

Legal Events